Morphiex Biotherapeutics | Biocentury Features Morphiex as a New and Emerging Company in the CD47 Space
593
post-template-default,single,single-post,postid-593,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Biocentury Features Morphiex as a New and Emerging Company in the CD47 Space

Check out the new Biocentury article featuring Morphiex Biotherapeutics’ as an emerging company which details how its CD47 immunotherapy platform is differentiated in both safety and efficacy for the treatment of cancer. Our lead drug candidate, MBT-001, is the only drug shown to block the SIRPa “Don’t eat met” and Thrombospondin-1 components of the CD47 immune checkpoint.
https://www.biocentury.com/biocentury/emerging-company-profile/2019-11-22/morphiex-enters-cd47-race-antisense-approach-

About MBT-001

MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. In addition, Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn